Palforzia Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The palforzia market research report is one of a series of new reports that provides palforzia market statistics, including palforzia industry global market size, regional shares, competitors with a palforzia market share, detailed palforzia market segments, market trends and opportunities, and any further data you may need to thrive in the palforzia industry. This palforzia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing global prevalence of peanut allergies, expansion of indications for palforzia use, rising consumer awareness of immunotherapy options, and increased focus on personalized medicine. Major trends in the forecast period include advancements in oral immunotherapy (OIT) technology, digital health integration for allergy management, artificial intelligence in allergy treatment personalization, smart devices for monitoring and managing peanut allergies, and enhanced drug delivery systems for oral immunotherapy.

The increasing prevalence of allergies is expected to drive the growth of the Palforzia market in the coming years. An allergy occurs when the immune system reacts abnormally to substances, or allergens, that are typically harmless, such as pollen, dust, or certain foods. This reaction can trigger symptoms ranging from mild discomfort such as sneezing or rashes to severe, life-threatening responses such as anaphylaxis. The rise in allergies is largely influenced by factors such as environmental changes, pollution, genetics, and lifestyle factors, including diet, hygiene practices, and greater exposure to allergens. Palforzia is a treatment for peanut allergies that uses oral immunotherapy to gradually desensitize the immune system to peanut proteins, helping to reduce the severity of allergic reactions, including anaphylaxis, caused by accidental peanut exposure. According to NHS England in August 2024, hospital admissions for allergies and anaphylaxis increased to 32,300 in 2023-24, up from 25,702 in 2022-23, highlighting the growing prevalence of allergies, particularly peanut allergies, which is driving the demand for Palforzia.

A key trend in the Palforzia market is the expansion of FDA-approved allergen treatments such as oral immunotherapy (OIT) to enhance the effectiveness and safety of peanut allergy treatments. OIT involves administering small, controlled doses of an allergen, such as peanut protein, to gradually desensitize the immune system and lessen the severity of allergic reactions. For example, in July 2024, Stallergenes Greer, a Switzerland-based company, received FDA approval to extend Palforzia’s pediatric indication. This approval provides more widespread access to allergy immunotherapy, helping to address peanut allergies by desensitizing patients over time through a gradual dose escalation process. Palforzia is available in powder form, with dosage levels adjusted to the patient’s tolerance.

In September 2023, Stallergenes Greer acquired Palforzia from Nestlé SA for an undisclosed amount. This acquisition allows Stallergenes Greer to expand its food allergy treatment portfolio and strengthen its position in the allergy treatment market. Nestlé, a global leader in food, beverages, nutrition, and health sciences, originally developed Palforzia as part of its commitment to providing innovative treatments for food allergies. This move by Stallergenes Greer reflects a growing focus on enhancing food allergy therapies.

The key company operating in the palforzia market is Stallergenes Greer International AG.

North America was the largest region in the palforzia market in 2024. The regions covered in palforzia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the palforzia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Palforzia is an oral immunotherapy (OIT) medication designed to help reduce the severity of allergic reactions, including anaphylaxis, in individuals with a confirmed peanut allergy. It is specifically approved for children and adolescents aged 4 through 17, though its use may be continued in older patients under medical supervision.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Palforzia include treatment of peanut allergies, the maintenance phase of oral immunotherapy (OIT), and peanut allergies with a risk of severe reactions. Treatment typically involves avoiding peanuts and managing symptoms with emergency medications for severe reactions. Palforzia is distributed through retail pharmacies, specialty pharmacies, and healthcare facilities, and is used by various end users, including hospitals, clinics, ambulatory care settings, and home care environments.

The palforzia market consists of sales of products such as pre-measured oral capsules and powder sachets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.